retatrutide nejm 2023 obesity trial ly3437943 24.2%. That's the mean body weight reduction recorded in Retatrutide's Phase 2 — over 48 weeks, published in the New England Journal of Medicine. For context: that exceeded both semaglutide and Retatrutide: A Triple Agonist Shaping
Description
However, in vitro studies have demonstrated that its metabolite, GLP-1(936), has protective effects in neuronal and microglial cell lines [41]
These compounds do far more than support digestive comfort
To learn more about weight loss reported in studies of Ozempic, see the manufacturers website
None of this is medical advice
[2] Rodriguez, A
